



$+$ 

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



**Complete if Known**

Application Number	10/075,073
Filing Date	February 13, 2002
First Named Inventor	William Glen Harter, et al
Group Art Unit	<del>1643</del> 1624
Examiner Name	Unknown
Attorney Docket Number	A0000428-01-CFP

*(use as many sheets as necessary)*

Sheet 2 of 6

[illegible]

RECEIVED  
JUN 2 2002

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (If known)				
TNI	✓	EP	0 443 568 A1		Morimoto, et al	08/28/1991		
	✓	EP	0 443 568 B1		Morimoto, et al	06/12/1996		
	✓	EP	0 492 316 A1		Akimoto, et al	07/01/1992		
	✓	EP	0 502 725 A2		de Laszlo	09/09/1992		
	✓	EP	0 530 537 A1		Akimoto, et al	03/10/1993		
	✓	EP	0 416 740 A2		Smith, et al	03/13/1991		
	✓	EP	0 297 661 B1		Janssens, et al	09/16/1992		
	✓	EP	0 438 261 A2		Akimoto, et al	07/24/1991		
	✓	EP	0 297 661 A1		Janssens, et al	01/04/1989		
TNI	✓	EP	0 282 133 B1		Janssens, et al	07/28/1993		

**Examiner  
Signature**

Udon

Date \_\_\_\_\_

**Considered**

6-2204

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial

code (WIPO Standard S.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard S. 16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

+

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 3 of 6

**Complete if Kn wn - -**

Application Number	10/075,073
--------------------	------------

Filing Date	February 13, 2002
-------------	-------------------

First Named Inventor	William Glen Harter, et al
----------------------	----------------------------

Group Art Unit	<del>1645</del> 1624
----------------	----------------------

Examiner Name	Unknown
---------------	---------

Attorney Docket Number	A0000428-01-CFP
------------------------	-----------------

[illegible][illegible]

**Examiner  
Signature**

Date \_\_\_\_\_

**Considered**

6-22-04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: National Commission on Offenders, Washington, D.C.

Please type a plus sign (+) inside this box

+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

## Complete if Known

Application Number	10/075,073
Filing Date	February 13, 2002
First Named Inventor	William Glen Harter, et al
Group Art Unit	1645 / 624
Examiner Name	Unknown
Attorney Docket Number	A0000428-01-CFP

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
TNT	✓	MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors", Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361
	✓	CLARK, Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25
	✓	CHEN, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654
	✓	HIROTA, Kosaku, et al, "Synthesis of 6-Substituted Thieno[2,3-d]pyrimidine-2,4(1H,3H)-diones", J. Heterocycl. Chem., 1990; 27(3); pp 717-721
	✓	RAJAPPA, S., et al, "Synthesis of Thiophenes: Part III* - Further Variations in the Substitution Pattern", Indian J. Chem., Vol. 12, 1974; pp 1-3
	✓	HCAPLUS Abstract 1998: 542760; "Preparation of bicyclic-substituted hexahydrobenz [c] isoindoles as a1 adrenergic antagonists", 1998.
	✓	HCAPLUS Abstract 1990: 514925; "Pyrimidines. 65. Synthesis of 6-substituted thieno [2,3-d] pyrimidine-2 4(1H,3H) - diones", 1990.
	✓	HCAPLUS Abstract 1974: 463420: "Synthesis of thiophenes. III. Further variations in the substitution pattern", 1974.
	✓	Derwent Abstract 2000-687031/67, "New xanthine derivatives are inhibitors of cellular processes mediated by interleukin-12 for treating inflammatory responses e.g. chronic inflammatory disease, chronic intestinal inflammation, arthritis, psoriasis and asthma (Eng)", 2000.
	✓	Derwent Abstract 92-415690/50, "New Pyrimidinone derivs. are angiotensin II antagonists - for treating hypertension, congestive heart failure, renal failure, Alzheimer's disease, amnesia schizophrenia etc (Eng)", 1992.
TNT	✓	Derwent Abstract 92-302020/37, "New fused pyrimidone derivs. - are angiotensin II antagonists to treat hypertension, congestive heart failure, Alzheimer's disease, amnesia, anxiety, schizophrenia, etc. (Eng)", 1992.

Examiner  
Signature

*[Signature]*

Date

Considered

6/22/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



TECH CENTER 1600/2800

JUN 12 2002

RECEIVED

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 6

Complete if Known

Application Number	10/075,073
Filing Date	February 13, 2002
First Named Inventor	William Glen Harter, et al
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	A0000428-01-CFP

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
TMT	✓	Derwent Abstract 91-254180/35, "New angiotensin-II antagonising fused thiophene derivatives - used for treating hypertension and circulatory diseases including heart diseases and stroke", 1991.
	✓	Derwent Abstract 89-192246/26, "New 3-piperidinyl:alkyl-thieno: or furo pyrimidine-2,4-dione cpds. - useful as serotonin antagonists and alpha adrenergic blockers", 1989.
	✓	Derwent Abstract 2000-195023/17, "New ipiperazinyl pyrimidine dione derivatives used as selective alpha-1D adrenoceptor antagonists for treating benign prostatic hyperplasia, hypertension, detrusor instability and incontinence (Eng)", 2000.
	✓	Derwent Abstract 2001-158207/16, "New piperazinyl pyrimidine dione derivatives are selective alpha-1D adrenoceptor antagonists used for treatment of e.g. hypertension", 2001.
	✓	Derwent Abstract 96-362624/36, "New bi:cyclic substd. hexa:hydro-benz-isoindole derivs. - are alpha-1 adrenergic antagonists, used in treatment of benign prostatic hyperplasia (Eng)", 1996.
	✓	Derwent Abstract 89-008928/02, "New bi:cyclic heterocycle substd. hexa-hydro-1H-azepine - and pyrrolidine cpds., have anti-histaminic properties, for treatment of e.g. allergic rhinitis, allergic asthma, etc.", 1989.
	✓	Derwent Abstract 88-258874/37, "New 1-alkyl substd. benzimidazole derivs. - having anti-histaminic activity and used for treating allergic diseases such as allergic asthma", 1988.
	✓	Derwent Abstract 91-216939/30, "New condensed heterocyclic glutemic acid derivs., - active against enzyme using folic acid and antitumour agents for treating e.g. leukemia", 1991.
	✓	Derwent Abstract 99-080786/07, "New thiophene- and pyrrole-based hetero-aromatic compounds - are (ant)agonists of cell surface receptors, useful e.g. for inhibiting unwanted cell growth e.g. due to cancer (Eng.)", 1999.
	✓	Derwent Abstract 97-165234/15, "New thieno-pyrimidine derivs. are endothelin antagonists - useful for treating e.g. acute renal failure, cardiac infarction, liver insufficiency, organ hypo-function and vasoconstriction (Eng)", 1997.
TMT	✓	Derwent Abstract 96-384384/38, "New 2,4(1H, 3H)-di:oxo-5-(aminoalkyl)thieno(2,3-d)-pyrimidine derivs. - are gonadotropin-releasing hormone antagonistic agents useful in prevention and treatment of sex hormone dependent diseases (Eng)", 1996.

Examiner  
Signature

*[Signature]*

Date  
Considered

6/22/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



JUN 12 2002

RECEIVED

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 6

Application Number	10/075,073
Filing Date	February 13, 2002
First Named Inventor	William Glen Harter, et al
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	A0000428-01-CFP

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
TM	✓	Derwent Abstract 95-382760/49, "Fused bicyclics as gonadotropin releasing hormone antagonists - used for treating hormone related cancers, benign prostatic hypertrophy, acne vulgaris, etc. (Eng)", 1995.
	✓	Derwent Abstract 93-299636/38, "New condensed heterocyclic oligo-glutamate derivs. - used as water soluble antitumour agent and have good storage stability in cells", 1993.
	✓	Derwent Abstract 93-078155/10, "New antitumour condensed pyrimidine derivs. - for treating chorlocarcinoma, leukaemia, breast adenocarcinoma, squamous cell carcinoma, lung cancer, lympho sarcoma, etc. and also rheumatism (Eng)", 1993.
	✓	Derwent Abstract 92-218561/27, "Antitumoural condensed heterocyclic oligo:glutamate derivs. - for treating leukaemia, squamous cell carcinoma, lymphatic sarcoma, small cell cancer of the lung etc. (Eng)", 1992.
	✓	Derwent Abstract 96-267825/27, "New hexa:hydro benz(e)isoindole cpds. - are useful in treatment of benign prostatic hyperplasia (Eng)", 1996.
	✓	Derwent Abstract 94-248420/30, "Furano- and thieno- (3,2-c)piperidone carboxamido-acids - are fibrinogen receptor antagonists, inhibit blood platelet aggregation, used in thrombi and emboli treatment: ", 1994.
	✓	Derwent Abstract 91-075241/11, "Heterocyclic peptide derivs. useful as renin inhibitors - in the treatment of hypertension, congestive heart failure; retro-viral diseases and central nervous system disorders", 1991.
TM	✓	HCAPLUS Abstract 1996:580284: "Preparation of heterocyclyl-substituted benz[3]isoindoles as x1 adrenergic antagonists", 1996.

Examiner  
Signature

*U. G. Harter*

Date

Considered

6-22-04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.